MDMAAn 'entheogen' aka Molly, Adam, Ecstasy
MDMA is under study in clinical trials to see if it can be helpful for mental health conditions when taken during psychotherapy. A range of effects can be experienced after ingesting MDMA - euphoria, feeling of interconnectedness, feelings of love and compassion, unity with nature and the universe, bliss, and anxiety. Emotions can feel more intense and profound. In a clinical setting with trained therapists, a person undergoing MDMA treatment is first prepared for the experience in 90-minute therapy sessions before embarking in all-day MDMA-assisted psychotherapy sessions (2-3 sessions, spaced 1 month apart). The therapeutic process continues in follow-up integration sessions where the person reflects on the journey, stabilizes insights, and establishes a plan for their healing to continue outside the therapy room.
In 2017, the FDA granted a Breakthrough Therapy designation for MDMA-assisted psychotherapy for the treatment of PTSD. Preliminary evidence showed MDMA was a substantial improvement over available PTSD medications (SSRIs). Clinical trials are now in the last phase of testing (phase 3). If significant MDMA could become approved for the treatment of PTSD by 2023.
MAPS has an Expanded Access Program, also known as ‘compassionate use’, for 50 qualifying individuals with chronic PTSD to receive MDMA-assisted psychotherapy outside of the phase 3 trials. Safety and tolerability data will be collected at the participating trial sites. Patients must pay for the treatment.
Check back with us, MAPS Expanded Access Sites are coming soon!